Review article: Measuring disease severity in inflammatory bowel disease – Beyond treat to target

IF 6.6 1区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Alimentary Pharmacology & Therapeutics Pub Date : 2024-10-15 DOI:10.1111/apt.18231
Akhilesh Swaminathan, Andrew S. Day, Miles P. Sparrow, Laurent Peyrin-Biroulet, Corey A. Siegel, Richard B. Gearry
{"title":"Review article: Measuring disease severity in inflammatory bowel disease – Beyond treat to target","authors":"Akhilesh Swaminathan,&nbsp;Andrew S. Day,&nbsp;Miles P. Sparrow,&nbsp;Laurent Peyrin-Biroulet,&nbsp;Corey A. Siegel,&nbsp;Richard B. Gearry","doi":"10.1111/apt.18231","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Inflammatory bowel disease (IBD) follows a heterogenous disease course and predicting a patient's prognosis is challenging. There is a wide burden of illness in IBD and existing tools measure disease activity at a snapshot in time. Comprehensive assessment of IBD severity should incorporate disease activity, prognosis, and the impacts of disease on a patient. This review investigates the concept of disease severity in adults with IBD to highlight key components contributing to this.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>To perform this narrative review, a Medline search was conducted for full-text articles available at 1st March 2024 using search terms which encompassed disease activity assessment, disease severity, prognosis, natural history of Crohn's disease (CD) and ulcerative colitis (UC), and the burden of IBD.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Current methods of disease assessment in IBD have evolved from a focus on the burden of symptoms to one that includes inflammatory targets, genetic, serological, and proteomic profiles, and assessments of quality-of-life (QoL), disability, and psychosocial health. Longitudinal studies of IBD suggest that the burden of illness is driven by disease phenotype, clinical markers of complicated disease course (previous intestinal resection, corticosteroid use, perianal disease in CD, recent hospitalisations in UC), gut inflammation, and the impact of IBD on the patient.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>Disease severity in IBD can be difficult to conceptualise due to the multitude of factors that contribute to IBD outcomes. Measurement of IBD severity may better encapsulate the full burden of illness rather than gut inflammation alone at a single timepoint and may be associated with longitudinal outcomes.</p>\n </section>\n </div>","PeriodicalId":121,"journal":{"name":"Alimentary Pharmacology & Therapeutics","volume":"60 9","pages":"1176-1199"},"PeriodicalIF":6.6000,"publicationDate":"2024-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/apt.18231","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Alimentary Pharmacology & Therapeutics","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/apt.18231","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background

Inflammatory bowel disease (IBD) follows a heterogenous disease course and predicting a patient's prognosis is challenging. There is a wide burden of illness in IBD and existing tools measure disease activity at a snapshot in time. Comprehensive assessment of IBD severity should incorporate disease activity, prognosis, and the impacts of disease on a patient. This review investigates the concept of disease severity in adults with IBD to highlight key components contributing to this.

Methods

To perform this narrative review, a Medline search was conducted for full-text articles available at 1st March 2024 using search terms which encompassed disease activity assessment, disease severity, prognosis, natural history of Crohn's disease (CD) and ulcerative colitis (UC), and the burden of IBD.

Results

Current methods of disease assessment in IBD have evolved from a focus on the burden of symptoms to one that includes inflammatory targets, genetic, serological, and proteomic profiles, and assessments of quality-of-life (QoL), disability, and psychosocial health. Longitudinal studies of IBD suggest that the burden of illness is driven by disease phenotype, clinical markers of complicated disease course (previous intestinal resection, corticosteroid use, perianal disease in CD, recent hospitalisations in UC), gut inflammation, and the impact of IBD on the patient.

Conclusions

Disease severity in IBD can be difficult to conceptualise due to the multitude of factors that contribute to IBD outcomes. Measurement of IBD severity may better encapsulate the full burden of illness rather than gut inflammation alone at a single timepoint and may be associated with longitudinal outcomes.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
评论文章:衡量炎症性肠病的疾病严重程度--从治疗到靶向
背景 炎症性肠病(IBD)的病程各不相同,预测患者的预后具有挑战性。IBD 患者的疾病负担很重,现有的工具只能测量疾病活动的时间快照。对 IBD 严重程度的全面评估应包括疾病活动性、预后和疾病对患者的影响。本综述研究了成人 IBD 患者疾病严重程度的概念,以强调导致疾病严重程度的关键因素。 方法 为了撰写这篇叙述性综述,我们在 Medline 上检索了截至 2024 年 3 月 1 日的全文文章,检索词包括疾病活动性评估、疾病严重程度、预后、克罗恩病(CD)和溃疡性结肠炎(UC)的自然史以及 IBD 的负担。 结果 目前的 IBD 疾病评估方法已从关注症状负担发展到包括炎症目标、遗传学、血清学和蛋白质组学特征,以及生活质量(QoL)、残疾和社会心理健康评估。IBD 的纵向研究表明,疾病负担是由疾病表型、复杂病程的临床标志物(既往肠切除术、皮质类固醇的使用、CD 的肛周疾病、UC 的近期住院治疗)、肠道炎症以及 IBD 对患者的影响所驱动的。 结论 由于导致 IBD 结果的因素众多,因此很难对 IBD 的疾病严重程度进行概念化。对 IBD 严重程度的测量可能会更好地概括疾病的全部负担,而不是仅仅测量单一时间点的肠道炎症,并且可能与纵向结果相关。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
15.60
自引率
7.90%
发文量
527
审稿时长
3-6 weeks
期刊介绍: Alimentary Pharmacology & Therapeutics is a global pharmacology journal focused on the impact of drugs on the human gastrointestinal and hepato-biliary systems. It covers a diverse range of topics, often with immediate clinical relevance to its readership.
期刊最新文献
Development and Validation of a PIVKA-II-Based Model for HCC Risk Stratification in Patients With HCV-Related Cirrhosis Successfully Treated With DAA Editorial: Is There a Role for Therapeutic Drug Monitoring of Subcutaneous Infliximab in Patients With Inflammatory Bowel Disease? Editorial: Updated COVID-19 Boosters-Tailoring Protection for Patients With IBD. Authors' Reply. Review Article: Green Management of IBD-New Paradigms for an Eco-Friendly Approach. Subcutaneous Infliximab Concentration Thresholds for Mucosal and Transmural Healing in Patients With Crohn's Disease.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1